At Elixir Software, we’re always excited to see how technology can bring people and ideas together, especially in the fast-paced world of drug discovery. One of the latest examples of that is the recent collaboration between PI Health Sciences (PIHS) and Cresset, where PIHS has adopted the Torx® platform to help streamline and accelerate their small molecule discovery work.

Torx® is a cloud-based platform developed by Cresset that brings the whole DMTA (Design-Make-Test-Analyze) cycle into one shared space. For teams working in drug discovery, that means better collaboration, clearer visibility, and faster decisions. PIHS is using Torx® to bring together their chemists, biologists, computational scientists, and project managers so they can all work more closely and efficiently—both internally and with their clients.

It’s a move that reflects PIHS’s commitment to innovation and operational excellence. With Torx®, they can stay agile, adapt quickly to new data, and keep projects moving without the usual delays caused by siloed systems or fragmented workflows.

While the spotlight here is rightly on the power of the Torx platform, we’re proud that Elixir’s iTraX technology is playing a supportive role in making it all run smoothly.

iTraX is the engine behind the workflow and resource management tools used in parts of Torx®—specifically in the ‘Make’ and ‘Test’ modules. It helps track tasks, manage samples, and coordinate the day-to-day activities that keep research moving. Think of it as the behind-the-scenes system that makes sure everyone knows what’s happening, what’s next, and where everything is.

It’s not about taking center stage—it’s about helping great teams do their best work, without friction.

For PIHS, the adoption of Torx is more than just a tech upgrade. It’s about building an infrastructure that supports collaboration, transparency, and high-quality science. With tools like iTraX helping things run in the background, their teams are free to focus on the big picture: discovering and delivering better treatments.

We’re thrilled to support that mission, and we’re looking forward to seeing what the future holds as this collaboration grows.